The clinical trials, ClinicalTrials.gov NCT identifiers: NCT02208362, NCT01454596, NCT01109095, targeting IL-13Rα2, EGFRvIII, and HER2, respectively, provide useful insights on the immunotherapeutic ability of CAR T cells against gliomas (Migliorini et al., 2018). Here, IL13RA2 is linked to central nervous system cancer.